The University of Oxford and the Serum Institute of India (SII) have started the world's first human trial of a vaccine ...

Serum Institute of India has partnered with Gates Medical Research Institute to manufacture M72/AS01E, a tuberculosis vaccine ...

India's Serum Institute of India (SII) has announced that it will manufacture an experimental tuberculosis (TB) vaccine under ...

Tuberculosis remains world’s deadliest infectious disease despite being preventable and curable. Around 1.23 million of 10.7 ...

The Gates Medical Research Institute (Gates MRI) has signed an agreement with Pune-based Serum Institute of India Private Limited (SII) to manufactur ...

Pune: Serum Institute of India (SII) and Gates Medical Research Institute (Gates MRI) have entered an agreement to ...

Oxford and Serum Institute have launched the first human trial of a vaccine targeting the deadly Bundibugyo strain of Ebola ...

Gates MRI and Serum Institute partner to manufacture a novel TB vaccine, investing $100 million for scalable production.

The Serum Institute of India rapidly produced 620,000 doses of the ChAdOx1 Bundibugyo ebolavirus vaccine and supplied 4,000 ...

The Gates Medical Research Institute and Serum Institute of India have signed an agreement to mass-produce the M72/AS01E ...

The study is expected to begin in the first quarter of 2027 & enrol around 1,000 patients in Brazil, Malaysia & Thailand. SII ...

Serum Institute will invest over US$100 million to manufacture the M72/AS01E vaccine if approved, a breakthrough that could become the world's first new tuberculosis vaccine in more than a century. In ...